A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma

Overview of attention for article published in Frontiers in oncology, October 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 8 X posts from 5 X users, with an upper bound of 21,104 followers.

A3 Adenosine and #P2X7 #PurinergicReceptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma: Human #malignantpleuralmesothelioma (MPM) is a rare, but aggressive tumor of the serosal… https://t.co/b6rzzjTAHx #oncol

RT @FrontOncology: New research: A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Mal…

RT @FrontOncology: New research: A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Mal…

RT @RBiogical: A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of #MalignantPleuralMeso…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.